Qube Research & Technologies LTD Kinnate Biopharma Inc. Transaction History

Qube Research & Technologies LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$2.24 - $2.66 $13,325 - $15,824	5,949 Added 1900.64%	6,262 $16,000
Q4 2023 Feb 13, 2024	SELL	$1.07 - $2.5 $4,609 - $10,770	-4,308 Reduced 93.23%	313 $0
Q3 2023 Nov 13, 2023	SELL	$1.38 - $3.31 $67,902 - $162,868	-49,205 Reduced 91.41%	4,621 $6,000
Q2 2023 Aug 14, 2023	BUY	$2.33 - $6.84 $125,414 - $368,169	53,826 New	53,826 $163,000
Q1 2021 May 14, 2021	SELL	$26.99 - $40.0 $163,883 - $242,880	-6,072 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$36.35 - $45.25 $220,717 - $274,758	6,072 New	6,072 $242,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.